School of Biomedical Sciences

• Position
  Lecturer in Biochemistry
• Campus
  Wagga Wagga
• Office
  Building 3, Room Nr 110
• Phone
  (+61-2/ 02) 6933 2729
• Fax
  (+61-2/ 02) 6933 2587

I completed a BSc (hons I) in Zoology and Biochemistry from the School of Biological Sciences at the University of NSW, Sydney, and subsequently obtained my PhD in Molecular Cell Biology (on proto-oncogene c-fos gene regulation and signal transduction) as an external student of the Department of Pathology, School of Medicine of the University of NSW. The laboratory work for my doctoral degree was performed in the group of Prof. Alfred Nordheim, who was then at the Institute of Molecular Biology at the Medizinische Hochschule Hannover, in Germany. After doing my PhD and follow-up postdoc work in Hannover I spent one year as a postdoctoral Scientist working on Fos-family gene regulation at The John Curtin School of Medical Research at the Australian National University in Canberra, where I was introduced through a guest lecture by Professor Keith Williams to the then emerging field of Proteomics. Working in the field of signal transduction, I was then trying to identify kinases that anonymously phosphorylated my target proteins, only to frustratingly vanish unidentified back into the cloaking shadows of the unchartered cytoplasm from whence they had appeared. This field of proteomics offered new strategies to tackle the biology cell signalling, and indeed the broad panorama of cell biology.

These were exciting developments, and I decided immediately that I wanted to work in proteomics because it showed the potential to eventually address just the questions that I was trying to ask in my own research. At that stage (in 1996) the Australian Proteome Analysis Facility (APAF) had just been established, and I assessed that there was no chance of my securing funds in Australia to work on proteomics. Therefore I moved back to Germany where my Ex-PhD supervisor, Alfred Nordheim, had just accepted a Professorship at the Department of Molecular Biology, Interfaculty Institute of Cell Biology at the University of Tuebingen, and he offered me the opportunity to initiate proteomics activities in his brand new and empty institute. Those activities were the direct genetic ancestor of the modern Proteomics Centre at Tuebingen, which was founded in 2000.

However before that centre was officially opened I had left academia. Realising that proteomics techniques detected only a fraction of all cellular proteins, I was working on strategies to improve protein detection: involving a vision of large two-dimensional protein separation gels combined with sensitive multiplexed radioactive protein detection. This led to my co-foundation of a proteomics-based biotechnology company in February 2000. One year later that company underwent a corporate merger to form ProteoSys AG, based in Mainz Germany, where I initially served on the managerial board and as Chief Research Officer and co-founding scientist until I left to return to Australia in 2007. At ProteoSys, with the support of a talented team of colleagues, we were able to develop the technological proteomics platform envisioned in the business plan and to experimentally focus those newly acquired tools onto several cancer systems. Those methods in turn revealed exciting cell biology, which closed the circle on my professional interests of oncogenic signal transduction. In 2008 I ‘moved back home’ by re-entering academic life in Australia as a biochemistry lecturer at Charles Sturt University in Wagga Wagga, where the climate and landscape are similar to Wellington NSW, where I grew up. And here I am.

 

top of page ^

Teaching

Teaching philosophy
I teach using a blended learning approach where students have access to multiple media and avenues to achieve their learning objectives. These range from face to face lectures, podcasting, linking to online e-resources, lab practicals, problem based learning modules, and one-on-one mentoring, as well as answering student queries by email, telephone, BLOG thread, or chat. My door is always open to students, but they are advised to make an appointment if they want to be certain that I am available.

Current subjects taught

• BCM210 Foundations & Techniques in Biochemistry (Lecturer).
• BCM211 Foundations in Biochemistry (Lecturer).
• BMS241 Molecular Cell Biology (Subject Coordinator & Lecturer).
• BMS243 Nutrition, Metabolism & Human Disease (Subject Coordinator & Lecturer).
• BMS301 Medical Science Special Topic. (Intense 1:1 student supervision).
• DOH231 Dental Biochemistry

Honours coordinator
Additionally, I am the honours course coordinator for the School of Biomedical Sciences, including coordination of

• 4508BP - Bachelor of Pharmacy (Honours)
• 4502BM - Bachelor of Biotechnology (Medical) (Honours)
• 4509HS - Bachelor of Health Science (Honours)
• 4514HN - Bachelor of Medical Science (Honours)

 

top of page ^

Research

I am a Key Researcher at the CSU Centre For Inland Health, in the research grouping Cell Biology, Genetics & Immunology In Health & Disease

Research Interests

• Signal transduction
• Proteomics technologies and their application
• Cancer research
• The role of PGRMC1 in cancer signaling and cellular metabolic regulation
• Human ageing

The role of PGRMC1 in cancer and metabolic regulation

At ProteoSys AG, a proteomics-centred company which I co-founded, I headed cancer research. After that indication area was discontinued due to insufficient funds I could choose any result in the then current cancer portfolio to pursue in an academic career. By far the most promising protein in the cancer portfolio of ProteoSys, the veritable jewel in the crown, was the protein Progesterone Receptor Membrane Component 1 (PGRMC1), which we had detected to be differentially phosphorylated between breast cancers differing in expression levels of the estrogen receptor. Whereas these results had been submitted for patent applications between 2004-2007 (WO2006029836; WO2007039189; WO2008037449), a chronic internal funding shortage for the project within the company had prevented the level of biological characterisation that will be necessary to elucidate the precise role of PGRMC1 in cancer. That elucidation represents my current research priority. Although it is a small protein, PGRMC1 has been implicated in a wide variety of biological functions (See Cahill 2007). In fact it is highly likely that PGRMC1 is involved at a crucial nexus position in a convergent inter-regulated yet hitherto undescribed signalling system (which includes the regulation of steroid synthesis) whose activity determines the survival prognosis of cancer cells (Neubauer et al., 2008). PGRMC1 also regulates the steroid-mediated onset of vasculogenesis that is so crucially important in metastatic biology (Neubauer et al., 2009), and is induced at the time and place in cancers where it regulate the onset of oxygen-independent tumour-specific energy metabolism (Figure 1)

Figure 1. The induction of PGRMC1 (red) in the hypoxic zone (redox stress) surrounding the necrotic core (central dark green staining) of a ductal carcinoma in situ from a breast cancer patient tissue section. The estrogen receptor (outer green staining) stains in a halo surrounding the hypoxic zone but is downregulated where PGRMC1 is upregulated; From Neubauer et al., (2008). In the same paper we showed that PGRMC1 phosphorylation differed between breast cancers, and that phosphorylation site mutants protected cancer cells from redox induced death.

Projects available on PGRMC1

There are several potential research projects available to study the role of this exciting protein in cancer and cell metabolism. Methods involve cell imaging, cloning, mutagenesis, cell culture, and general cell molecular biological techniques. Students interested in pursuing Honours or Doctoral studies in a stimulating scientific environment working on the mechanistic molecular cell biology of cancer or pharmacology are encouraged to contact me. The commitment to either undergraduate or postgraduate study is a vitally important step that hones the future career path of any student. The PGRMC1 signalling project offers a scientific environment and a compellingly urgent research topic that will enable students who are willing to apply themselves to reach their scientific potential at this crucial stage of their careers. The School of Biomedical Sciences is also a great place to work, and we have a lot of fun here too!

Human Ageing

The earliest stories passed down to us in myths and sagas contain reference to secret and powerful treatments that could prolong the ageing process in those that took them, or to extremely long lived gods or royal characters. These include the Indo-European gods (e.g., the apples of the Hesperides and Ambrosia  in Greek, the apples of Idun and Mead for the Germanic Aesir, Homa and Soma for the early Indo-Iranians), Manetho’s long lived early predynastic Egyptian kings, the Epic of Gilgamesh (the earliest attested literature, where the survivor of Noah’s flood had the secret of immortality), and the related flood account in Genesis, where Noah’s immediate male ancestors all lived many hundreds of years, including Methuselah, the oldest of them all (“But what good is livin’, when no girl will give-in to a man who is 900 years”). Clearly, this theme has long aroused the excitement of many story tellers.

Since the late 1990’s I have been interested in ageing models in model organisms. Over the past two decades these have revealed evolutionarily conserved pathways that affect the rate of ageing in organisms from yeast, roundworms, and fruit flies to mice (Guarente & Kenyon, 2000; ), and leading to speculation that ageing may be a treatable phenomenon in the future (Hadley et al., 2005). One such pathway involves the mTOR (mammalian Target Of Rapamycin) signalling pathway. Experimental results in model organisms over the last 20 years have led to the recent demonstration that inhibiting mTOR in mice with the dug rapamycin indeed delays the rate of ageing of those mice (Harrison et al., 2009). Although the effect was relatively modest, and rapamycin is an immune immunosuppressant that destroyed the immune systems of those mice, this represented a veritable landmark result that demonstrated both proof of concept and proof of mechanism that ageing can be pharmacologically addressed in mammals. These are the two major acceptance criteria for the pharmaceutical industry to accept a project into their high throughput screening pipelines. It is quite feasible (but don’t hold your breath) that in the foreseeable future humans may age more slowly, so that a 65 year old person may have the body of a modern twenty year old. The advent of antibiotics after WWII heralded a medical revolution of similar importance, and such a breakthrough in ageing research is quite within the realms of possibility in the coming years. These are exciting times, and just perhaps there will one day be middle-aged men many centuries old who women will still find attractive.

 

top of page ^

Publications

Book Chapters

• Wozny W, Schwall GP, Sastri CS, Poznanović S, Stegmann W, Hunzinger C, Groebe K, Cahill MA. 2009. Differential ProteoTope radioactive quantification of protein abundance ratios. Chapter 42 in: Protein Protocols Handbook (3rd ed). JM Walker (Ed). Meth Mol Biol (Humana, NY). ISBN: 978-1-58829-880-5. pp. 449-477, In press. Due: October 2009
• Poznanović S, Wozny W, Zengerling H, Schwall GP, Cahill MA. 2009. 54 cm Serial Immobilized pH Gradient Isoelectric Focusing Over pH 4-9. Chapter 30 in: Protein Protocols Handbook (3rd ed). JM Walker (Ed). Meth Mol Biol (Humana, NY). ISBN: 978-1-58829-880-5. pp. 269-277, In press. Due: October 2009
• Neubauer H, Fehm T, Schuetz C, Speer R, Solomayer E, Schrattenholz A, Cahill MA, Kurek R. 2007. Proteomic expression profiling of breast cancer. In: Recent Results in Cancer Research, 176:89-120 Targeted Therapies in Cancer. Dietel M (Ed). (Springer, Berlin) ISBN:3-540-46090-X.
• Cahill MA, Nordheim A. 2001. Proteome research in an academic environment. In: Proteomics: from protein sequence to function. Pennington SR & Dunn MJ (Eds). (New York: Bios Scientific Publishers Ltd.), pp. 277-288.
• Cahill MA., Althöfer H, Nordheim A. 1996. MADS-domain transcription factors and their accessory proteins (TCFs): nuclear targets for growth control signals. In: Cancer Genes: Functional Aspects, Mihich E (Ed). (New York: Plenum Press), pp. 161-175.
• Cahill MA, Janknecht R, Nordheim A. 1995. Signal uptake by the c-fos serum response element. In: Inducible Gene Expression, Baeuerle PA (Ed). (Boston: Birkhäuser Press), pp. 39-73.

Peer-reviewed Publications

• Neubauer H, Adam G, Seeger H, Mueck AO, Solomayer E, Wallwiener D, Cahill MA, Fehm T. 2009. Membrane-Initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric. 12:230-9.
  http://www.ncbi.nlm.nih.gov/pubmed/19340614
• Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, Herrmann K, Schrattenholz A, Cahill MA, Schwaiger M, Hofler H, Wester HJ. 2008. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clinical Cancer Research. 14:8279-87.
  http://www.ncbi.nlm.nih.gov/pubmed/19088045
• Neubauer H, Clare S, Wozny W, Schwall GP, Poznanović S, Stegmann W, Vogel U, Sotlar K, Wallwiener D, Kurek R, Fehm T, Cahill MA. 2008. Breast cancer proteomics reveals correlation between Estrogen Receptor status and differential phosphorylation of PGRMC1. Breast Cancer Research. 10:R85.
  http://www.ncbi.nlm.nih.gov/pubmed/18922159
• Cahill MA. 2007. Progesterone Receptor Membrane Component 1: an integrative review. J Ster Biochem Mol Biol, 105:16-36. http://www.ncbi.nlm.nih.gov/pubmed/17583495
• Cahill MA, Vogt JA, Servos J, Wozny W, Schwall GP, Groebe K, Schrattenholz A, Stegmann W. 2007. Metabolically stable isotope labeling prior to electrophoretic protein separation reveals differences in fractional synthesis rates between mitochondrial aldehyde dehydrogenase isoforms. J Chromatogr A, 1161:67-70.
  http://www.ncbi.nlm.nih.gov/pubmed/17466314
• § Wozny W, Schroer K, Schwall GP, Poznanović S, Stegmann W, Dietz K, Rogatsch H, Schaefer G, Huebl H, Klocker H, Schrattenholz A, Cahill MA. 2007. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3. Proteomics, 7:313-322.
  http://www.ncbi.nlm.nih.gov/pubmed/17205602
• Hunzinger C, Wozny W, Schwall GP, Poznanović S, Stegmann W, Zengerling H, Schoepf R, Groebe K, Cahill MA, Osiewacz HD, Jägemann N, Bloch M, Dencher NA, Krause F, Schrattenholz A. 2006. Comparative Profiling of the Mammalian Mitochondrial Proteome: Multiple Aconitase-2 Isoforms including N-formylkynurenine modifications as part of a protein biomarker signature for reactive oxidative species. J Proteome Res, 5:625-33.
  http://www.ncbi.nlm.nih.gov/pubmed/16512678
• Neubauer H, Clare SE, Kurek R, Fehm T, Wallwiener D, Sotlar K, Nordheim A, Wozny W, Schwall GP, Poznanović S, Sastri C, Hunzinger C, Stegmann W, Schrattenholz A, Cahill MA. 2006. Breast cancer proteomics by laser capture microdissection, sample pooling, 54 cm immobilised pH gradient isoelectric focussing, and differential iodine radioisotope detection. Electrophoresis, 27:1840-52. http://www.ncbi.nlm.nih.gov/pubmed/16645950
• Poznanović P, Wozny W, Schwall GP, Sastri C, Hunzinger C, Stegmann W, Schrattenholz A, Buchner A, Gangnus R, Burgemeister R, Cahill MA. 2005. Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels. J Proteome Res,4:2117-25.
  http://www.ncbi.nlm.nih.gov/pubmed/16335957
• Poznanović P, Schwall G, Zengerling H, Cahill MA. 2005. Isoelectric focusing in serial immobilized pH gradient gels to improve protein separation in proteomic analysis. Electrophoresis, 26:3185-3190. http://www.ncbi.nlm.nih.gov/pubmed/16041705
• Vogt JA, Hunzinger C, Schroer K, Holzer K, Bauer A, Schrattenholz A, Cahill MA, Schillo S, Schwall G, Stegmann W, Albuszies G. 2005. Determination of fractional synthesis rates of mouse hepatic proteins via metabolic 13C-labeling, MALDI-TOF MS and analysis of relative isotopologue abundances using average masses. Anal Chem, 77:2034-42.
  http://www.ncbi.nlm.nih.gov/pubmed/15801735
• Schrattenholz A, Wozny W, Klemm M, Schroer K, Stegmann W, Cahill MA. 2005. Differential and quantitative molecular analysis of ischemia complexity reduction by isotopic labeling of proteins using a neural embryonic stem cell model. J Neurol Sci, 229-230:261-7. http://www.ncbi.nlm.nih.gov/pubmed/15760649
• Davezac N, Tondelier D, Lipecka J, Fanen P, Demaugre F, Debski J, Dadlez M, Schrattenholz A, Cahill MA, Edelman A. 2004. Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/deltaF508-CFTR to the plasma membrane. Proteomics, 4:3833-44.
  http://www.ncbi.nlm.nih.gov/pubmed/15529338
• Schrattenholz A, Klemm M, Cahill MA. 2004. Potential of comprehensive Toxico-Proteomics: Quantitative and Differential Mining of Functional Proteomes from Native Samples. ATLA (Alternatives To Laboratory Animals), 32 (Supplement 1):123-131.
  http://www.cababstractsplus.org/google/abstract.asp?AcNo=20043109968
• Kurek R, Neubauer H, Clare S, Sotlar K, Nordheim A, Cahill M, Poznanovic S, Berth M, Kolbe M, Wallwiener D. 2003. Identifikation differentiell exprimierter Proteine in unterschiedlichen Progressionsstufen von Mammakarzinomgewebe mittels Lasermikrodissektion und Proteomanalyse. Geburtsh Frauenheilk, 63:H-S 09.
  http://www.thieme-connect.com/ejournals/abstract/gebfra/doi/10.1055/s-2003-815167
• Vogt JA, Schroer K, Hölzer K, Hunzinger C, Klemm M, Biefang-Arndt K, Schillo S, Cahill MA, Schrattenholz A, Matthies H, Stegmann W. 2003. Protein abundance quantification in embryonic stem cells using incomplete metabolic labelling with 15N amino acids, MALDI-TOFMS, and analysis of relative isotopologue abundances of peptides. Rapid Comm Mass Spectrom, 17:1273-1282. http://www.ncbi.nlm.nih.gov/pubmed/12811750
• Cahill MA, Wozny W, Schwall G, Schroer K, Hölzer K, Poznanović S, Hunzinger C, Vogt JA, Stegmann W, Matthies H, Schrattenholz A. 2003. Analysis of relative isotopologue abundances for quantitative profiling of complex protein mixtures labelled with the acrylamide/D3-acrylamide alkylation tag system. Rapid Comm Mass Spectrom, 17:1283-1290. http://www.ncbi.nlm.nih.gov/pubmed/12811751
• Poland J, Cahill MA*, Sinha P. 2003. Isoelectric focusing in long immobilized pH gradient gels to improve protein separation in proteomic analysis. Electrophoresis, 24:1271-1275. (*corresponding author) http://www.ncbi.nlm.nih.gov/pubmed/12707921
• Vuong GL, Weiss, SM, Kammer W., Priemer M, Vingron M, Nordheim A, Cahill MA. 2000. Improved sensitivity proteomics by post-harvest alkylation and radioactive labelling of proteins. Electrophoresis, 21:2594-2605. http://www.ncbi.nlm.nih.gov/pubmed/10949135
• Heidenreich O, Neininger A, Schratt G, Zinck R, Cahill MA, Engel K, Kotlyarov A, Kraft R, Kostka S, Gaestel M, Nordheim A. 1999. MAPKAP Kinase 2 phosphorylates Serum Response Factor in vitro and in vivo. J Biol Chem, 274:14434-14443. http://www.ncbi.nlm.nih.gov/pubmed/10318869
• Cahill MA. 1997. c-Fos transrepression revisited. FEBS Lett, 400: 9-10.
  http://www.ncbi.nlm.nih.gov/pubmed/9000503
• Müller JM, Cahill MA, Rupec RA, Bäuerle PA, Nordheim A. 1997. Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1. Eur J Biochem, 244:45-52.
  http://www.ncbi.nlm.nih.gov/pubmed/9063444
• Cahill MA, Nordheim A, Xu YZ. 1996. Crosslinking of SRF to the c-fos SRE CArG box guanines using photo- active thioguanine oligodeoxynucleotides. Biochem Biophys Res Commun, 229:170-175. http://www.ncbi.nlm.nih.gov/pubmed/8954101
• Cahill MA, Janknecht, R., and Nordheim, A. 1996. Signalling pathways: Jack of all cascades. Curr Biol, 6: 16-19. http://www.ncbi.nlm.nih.gov/pubmed/8805215
• Cahill MA, Peter ME, Kischkel FC, Chinnaiyan AM. Dixit VM, Krammer PH, Nordheim A. 1996. CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene, 13:2087-96. http://www.ncbi.nlm.nih.gov/pubmed/8950975
• Müller JM, Cahill MA, Nordheim A, Bäuerle PA. 1996. The transcription factor TCF/Elk-1: a nuclear sensor of changes in the cellular redox status. Adv Exp Med Biol, 387:77-84.
  http://www.ncbi.nlm.nih.gov/pubmed/8794197
• Ernst, WH., Janknecht, R., Cahill, MA., and Nordheim, A. 1995. Transcriptional repression mediated by the serum response factor. FEBS Lett, 357:45-49.
  http://www.ncbi.nlm.nih.gov/pubmed/8001676
• Zinck R*, Cahill MA*, Kracht M, Sachsenmaier C, Hipskind RA, Nordheim A. 1995. Protein synthesis inhibitors reveal differential regulation of mitogen- activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1. Mol Cell Biol, 15:4930-4938. (*the first two authors contributed equally)
  http://www.ncbi.nlm.nih.gov/pubmed/7651411
• Janknecht R, Cahill MA, Nordheim A. 1995. Signal integration at the c-fos promoter. Carcinogenesis, 16:443-450. http://www.ncbi.nlm.nih.gov/pubmed/7697796
• Cahill MA, Ernst WH, Janknecht R, Nordheim A. 1994. Regulatory squelching. FEBS Lett, 344:105-108. http://www.ncbi.nlm.nih.gov/pubmed/8187867
• Cahill MA, Nordheim A, Janknecht R. 1994. Co-occurrence of CArG boxes and TCF sites within viral genomes. Biochem Biophys Res Commun, 205:545-551.
  http://www.ncbi.nlm.nih.gov/pubmed/7999077

Patent Applications

• USE OF AT LEAST ONE ISOFORM OF PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1 (PGRMC1). Publication info: WO2008037449 - 2008-04-03
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2008037449
• PHOSPHORYLATED OR NON-PHOSPHORYLATED MPR AS DIAGNOSTIC MARKER OR THERAPEUTIC TARGET. Publication info: WO2007039189 - 2007-04-12
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2007039189
• § ANNEXIN FOR CANCER RISK ASSESSMENT. Publication info: WO2006125580 - 2006-11-30 http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006125580
• BREAST CANCER PROTEINS. Publication info: WO2006029836 - 2006-03-23
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1789804
• § DIAGNOSTIC MARKER FOR CANCER. Publication info: WO2005078124 - 2005-08-25                 http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1720611
• SERIAL ISOELECTRIC FOCUSING OF IMMOBILIZED PH GRADIENTS. Publication info: WO2005026715 - 2005-03-24
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005026715
• ISOELECTRICAL FOCUSSING ON IMMOBILISED PH GRADIENTS. Publication info: WO2004023131 - 2004-03-18
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2004023131
• § Use of annexin A3, or other proteins, as diagnostic markers for cancer, especially of the prostate, also use of modulators of these markers for treating cancer. Publication info: Patent number: DE102004038076 - 2005-09-01
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=DE102004038076
• DIFFERENTIAL INDICATION OF LABELED MOLECULES. Publication info: WO03102627 - 2003-12-11
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO03102627
• METHOD FOR QUANTIFYING MOLECULES. Publication info: WO03098182 - 2003-11-27 http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO03098182
• USE OF SUBSTANCES FOR TREATING TUMORS. Publication info: WO03086461 - 2003-10-23 http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO03086461
• METHOD FOR SEPARATING, PURIFYING AND IDENTIFYING PROTEINS FROM PROTEIN MIXTURES. Publication info: WO02098904 - 2002-12-12
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO02098904
• IMPROVED PROTEIN ANALYSIS. Publication info: WO0194945 - 2001-12-13
  http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO0194945
• MICROPREPARATIVE ISOELECTRIC FOCUSSING. Publication info: WO0168225 - 2001-09-20 http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO0168225
• LABELLING OF PEPTIDES AND PROTEINS. Publication info: EP1059531 - 2000-12-13 http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1059531
• REVERSIBLY FIXED GELS FOR GEL ELECTROPHORESIS. Publication info: EP1059529 - 2000-12-13 http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1059529

§ Wozny et al. 2007 & patents DE102004038076, WO2005078124 & WO2006125580 led to a multicenter clinical trial with the title: “Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma” with Identifier: NCT00400894: http://clinicaltrials.gov/ct/gui/show/NCT00400894
These patents were licensed to bioMérieux Clinical Diagnostics (Marcy l'Etoile, France) in September 2008.
§ See also Am. Urol. Assoc. annual meeting 2007: Webcast of Prof. Fritz H. Schroeder, M.D. (slides 9-11):
http://webcasts.prous.com/aua2007/pop_up_bio.asp?sid=220&id=194&q=auto&v=auto&webcast=highlights&CID=&CLID=2

Invited Presentations

• Charles Sturt University, School of Biomedical Science Research Seminar Series. August 7th 2009. Towards the role(s) of the putative membrane steroid receptor PGRMC1 in breast cancer. M. Cahill.
• John Curtin School of Medical Research School Seminar Series, Australian National University. 31st July, 2009. Towards the role(s) of the putative membrane steroid receptor PGRMC1 in breast cancer. M. Cahill.
• St. Vincent’s Hospital Cancer Seminar Series, Melbourne. July 21st 2009. Towards the role(s) of the putative membrane steroid receptor PGRMC1 in breast cancer. M. Cahill.
• University of Newcastle, Cancer Research Unit Seminar, Newcastle NSW. 15th June 2009. Towards the role(s) of the putative membrane steroid receptor PGRMC1 in breast cancer. M. Cahill.
• Ludwig Institute for Cancer Research, Royal Melbourne Hospital. 5th June 2009. Towards the role(s) of the putative membrane steroid receptor PGRMC1 in breast cancer. M. Cahill.
• Monash Institute of Medical Research Seminar Series. Monash Centre for Cancer Research. 16th April 2009. Towards the role(s) of the putative membrane steroid receptor PGRMC1 in breast cancer. M. Cahill.
• Proteomic Forum 2009, March 29 to April 2, Berlin. Advisory board. Cahill M. (http://www.ctw-congress.de/proteomicforum2009/society_committees.html)
• 2nd BMBF Colloquium Proteomics: New efficient methods for functional proteome analysis. 30 May - 1 June 2005. Potsdam, Germany. ProteoTope analysis of cancer proteomes. Cahill M.
• 1st Annual Meeting of the Portugese Proteomics Network – ProCura. 17 November 2003. Lisbon, Portugal. Molecular Analysis of Complex Biological Systems. Cahill M.
• Computational Systems Biology (CSB) – Its future in Europe. Workshop organized by DG Research of the European Commission. 10-11 September 2003. Brussels. Embryonic stem cell differentiation: Possible elements of a coordination action. Cahill M.
• 1st BMBF Proteomics-Statusseminar. 11.-12. May, 2003. Bad Honnef, Germany. ProteoTope analysis of microdissected proteomes. Schwall G, Wozny W, Poznanovic S, C Sastri C, Kurek R, Clare S, Schroer K, Stegmann W, Schrattenholz A, Cahill MA.
• Forum Life Science 2003 together with the 21st DECHEMA Annual Biotechnology Meeting. 2-4 April 2003(3 April). Technical University of Munich, Garching, Germany. ProteoTope analysis of breast cancer genes. Cahill M, Wozny W, Sastri C, Kurek R, Clare S, Poznanovic S, Stegmann W, Schrattenholz A.
• GBM Workshop "Bioanalytik für junge Wissenschaftler", 6-8 November 2000, Rauischholzhausen (near Giessen) Germany. ProteoTope Proteomics. Cahill M.
• Electrophoresis Forum 99, October 25-27, 1999, Technical University of Munich, Garching. Improved sensitivity proteomics by post-harvest alkylation and radioactive labelling of proteins. Cahill M.

 

top of page ^

Grants

Academic Grants: M. Cahill at Charles Sturt University (commenced 07/2008)

Grant body	Ref	Status	Applicants	Title	Period	Σ value
Charles Sturt University Competitive Grants	A105-900-639-40002	funded	M. Cahill	Structures of the protein pgrmc1 in complex with its ligands heme and progesterone	2009-2010	AU$ 15,000
Charles Sturt University Publication Assistance Scheme	CSU A105-900-639-30007	funded	M. Cahill	Stable Isotope based Proteomics: An Approach for unbiased quantification and quality control	2009	AU$ 1,000
Charles Sturt University Grant-writing Assistance Scheme	CSU A105-900-639-40003	funded	M. Cahill	Anti-ageing properties of plants (Grant writing assistance)	2009	AU$ 1,000

Grants to ProteoSys AG written and/or managed by M. Cahill

ProteoSys AG was also involved in the following grants, which I either co-planned or managed within the company:

Granting body	Grant Title	Reference Number	Period	Financial Sum approved (To ProteoSys)
	MY ROLE
European FP6 PRIORITY 1 (LifeSciHealth)	Development of new technologies for low abundance proteomics: Application to cystic fibrosis. (NEUPROCF)	LSHG-CT-2005-512044	1.6.2005 – 31-5-2008	300,000.00 €
	I AUTHORED AND COSTED THE PROJECT APPLICATION FOR PROTEOSYS
European FP6 PRIORITY 1: (LifeSciHealth)	Role of Mitochondria in Conserved Mechanisms of Ageing (MIMAGE)	LSHM-CT-2004-512020	1.1.2005 – 31.12.2010	571,405.00 €
	I AUTHORED AND COSTED THE PROJECT APPLICATION FOR PROTEOSYS
European FP5 Quality of life management of living resources	Development of UltraSensitive methods for proteome: application to cystic fibrosisProposal Acronym : (EUROPROCF)	European FP5 Proposal Nr. QLRT 2000-01335	1.9.2001 – 31.8.2004	715,415.00 €
	I COAUTHORED AND COSTED THE PROJECT, & SUPERVISED THE PROJECT AT PROTEOSYS.
European FP5 Quality of life management of living resources	Prostate disorders: procurement of biomarkers & Pharmaceuticals (ProCure BioPharm)	European FP5 Proposal Nr. QLRT-2000-00159	1.1.2001 – 31.12.2004	214,291.00 €
	I PLANNED & COAUTHORED THE PROTEOMICS PROJECT, & REPRESENTED PROTEOSYS AG WITHIN THE CONSORTIUM.
German Human Genome Project§	Proteomanalyse von Brustkrebsgenen. Partners: Frauenklinik Tübingen, Decodon GmbH, Zellbiologie Tübingen	01 KW0102	1.9.2001 – 30.6.2005	554,595.75 €
	I COAUTHORED & PLANNED THE PROTEOMICS, & WAS CONSORTIUM COORDINATOR.
BMBF Proteomics§	Fraktionierung und Gewinnung von „Low Abundandance“ Proteinen in der Proteomanalytik.	0312831	1.11.2001- 31.12.2003	678,304.00 €
	I CONCEIVED & AUTHORED THE PROJECT, & WAS CONSORTIUM COORDINATOR.

§     I was consortium coordinator of these grants.

Academic Grants to M. Cahill at the University of Tuebingen

(Joint proteomics applications with Prof. Alfred Nordheim)

Granting body	Grant Title	Reference Number	Period	Financial Sum approved
	MY ROLE
Deutsche Forschungs Gesellschaft (DFG) Mass-Spectrometry Initiative.	Medizinische Proteomanalyse: massenspektrometrische Identifizierung von Proteinen klinischer Biopsate.	DFG 120/11-1 (A 227)	October 1999	DM 719,000
	I COAUTHORED THE GRANT WITH PROF. NORDHEIM. -> PE Biosystems Q-STAR purchase.
University Clinics of Tuebingen	MALDI TOF Purchase.	Tuebingen Clinics internal	August 1998	DM 400,000
	I COAUTHORED THE GRANT WITH PROF. NORDHEIM.

 

 

top of page ^